384 results about "Cardiac rhythms" patented technology

A system and method for monitoring and controlling the therapy of a cardiac rhythm abnormality victim at a remote site by proving immediate access to a medical professional at a central station. The method comprises the steps of: (1) providing a plurality of electrodes for receiving cardiac signals generated by the victim and for the application of electrical pulses to the victim at a remote site; (2) transmitting the signals from the remote site to a central station; (3) receiving the signals at the central station and displaying them for the medical professional; (4) selecting whether to delivery defibrillation or pacing therapy to the victim based on the medical professional's analysis of the signals (5) transmitting the selection results to the remote site; and (6) receiving the selection results at the remote site and applying the selected therapy to the victim.

A cardiac rhythm management system includes an atrial pacing preference (APP) filter for promoting atrial pacing. The APP filter includes an infinite impulse response (IIR) or other filter that controls the timing of delivery of atrial pacing pulses. The atrial pacing pulses are delivered at an APP-indicated pacing rate that is typically at a small amount above the intrinsic atrial heart rate. For sensed beats, the APP indicated rate is increased until it becomes slightly faster than the intrinsic atrial heart rate. The APP-indicated pacing rate is then gradually decreased to search for the underlying intrinsic atrial heart rate. Then, after a sensed atrial beat, the APP filter again increases the pacing rate until it becomes faster than the intrinsic atrial rate by a small amount. As a result, most atrial heart beats are paced, rather than sensed. This decreases the likelihood of the occurrence of an atrial tachyarrhythima, such as atrial fibrillation. The decreased likelihood of atrial tachyarrhythmia, in turn, decreases the likelihood of inducing a ventricular arrhythmia, either as a result of the atrial tachyarrhythmia, or as the result of delivering a defibrillation shock to treat the atrial tachyarrhythmia.

A neuro-stimulation system and method are provided which can monitor EKG signals and provide electrical stimulation. The system comprises a stimulation lead having at least one stimulating electrode on the lead and an IPG having a case and connectors. The connectors can mechanically and electrical connect to the lead and to the at least one stimulating electrode and an EKG electrode can be placed on the stimulating lead. The IPG case may be used variously as an EKG electrode, as well as an indifferent electrode. Alternatively or additionally, a separate, second lead having a second EKG electrode may be connected to the IPG. This second EKG electrode may also double in function as a stimulation electrode.

Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and / or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.

Systems and methods of detecting an impending cardiac decompensation of a patient measure an electrocardiogram signal of the patient. An incidence of cardiac arrhythmias is determined from the electrocardiogram signal. A risk of impending decompensation is determined in response to the incidence of cardiac arrhythmias. In many embodiments, the impending decompensation can be detected early enough to avoid, or at least delay, the impending decompensation, such that patient trauma and / or expensive ICU care can be avoided. Although embodiments make specific reference to monitoring electrocardiogram and other physiological signals with an adherent patch, the system methods and devices are applicable to many applications in which physiological monitoring is used, for example wireless physiological monitoring with implanted sensors for extended periods.

A method of conserving power and extending the life of a battery in an implantable rate-responsive cardiac rhythm management device. In accordance with the preferred embodiment, a first physiologic sensor is used to enable a power consuming feature only when the first sensor produces an output falling within a predetermined range and subsequently disables the power consuming feature when the output of the first sensor falls back outside the predetermined range. The first sensor may measure heart rate, physical movement, posture or other parameters and the power consuming feature may comprise further physiologic sensors, a different mode of pacing or a combination thereof.

A cardiorenal patient monitoring system comprising, either implanted or non-implanted device(s), remote peripheral device(s), computer network(s), host, and communication means between the device(s), computer network(s), and host. The preferred embodiment shows an advanced patient monitoring system for using an implanted cardiac device and a dialysis machine in renal therapy. In addition, the method of advanced patient monitoring is in conjunction with the advanced patient monitoring system is disclosed.

The present invention is directed toward a sensing architecture for use in cardiac rhythm management devices. The sensing architecture of the present invention provides a method and means for certifying detected events by the cardiac rhythm management device. Moreover, by exploiting the enhanced capability to accurately identifying only those sensed events that are desirable, and preventing the use of events marked as suspect, the sensing architecture of the present invention can better discriminate between rhythms appropriate for device therapy and those that are not.

A cardiac rhythm management apparatus includes a proximal housing, a distal housing and a lead. The proximal housing includes a first energy storage device. The distal module is implantable within a patient's heart, and includes a second energy storage device, at least one electrode, and a control module. The control module controls the delivery of at least one electrical stimulus from the second energy storage device to a location in communication with the patient's heart. The lead connects the proximal housing to the distal module and is configured to communicate one or more digital signals between the proximal housing and the distal module.

Described herein are devices and methods for improving the hemodynamic function of a patient. In particular, a first device adapted to reshape an atrio-ventricular valve is used in combination with a second device configured to further alter the blood flow through the valve. The first device is typically an implant positioned in the subvalvular space of a ventricle. The second device may be an annuloplasty implant, a non-annulus valve apparatus implant, a ventriculoplasty implant, or a cardiac rhythm management device.

A method and apparatus are provided for improving the detection of certain cardiac rhythms by combining dual chamber interval-related detection methods with electrogram morphology analysis. A prioritized set of rules are defined wherein each rule is directed at identifying a particular arrhythmia or type of arrhythmia. Each rule includes clauses that may be related to sensed event intervals and interval patterns and at least one rule includes at least one clause relating to the EGM morphology.

A cardiac rhythm management apparatus includes a proximal housing, a distal housing and a lead. The proximal housing includes a first energy storage device. The distal module is implantable within a patient's heart, and includes a second energy storage device, at least one electrode, and a control module. The control module controls the delivery of at least one electrical stimulus from the second energy storage device to a location in communication with the patient's heart. The lead connects the proximal housing to the distal module and is configured to communicate one or more digital signals between the proximal housing and the distal module.

The present invention provides a system and method for classifying cardiac beats based on activation-recovery intervals (ARIs) or an ARI-related parameter such as the spatial dispersion of activation, recovery or ARIs. The beat classification method may be used in monitoring and detecting cardiac rhythms and / or for controlling a cardiac stimulation therapy. The beat classification method includes acquiring a reference ARI for one or more known types of cardiac beats; measuring the activation-recovery interval of an unknown cardiac beat during cardiac activity monitoring; comparing the measured activation-recovery interval to the stored reference ARI(s); and classifying the cardiac beat based on the comparison between the measured ARI and the reference ARI(s).

The invention provides a cardiac rhythm management system for stimulating a heart having photosensitive tissue, vectors useful to photosensitize cells expressing the vectors, and methods for light induced depolarization of cells.

This document discusses a system that includes an intermediary telemetry interface device for communicating between a cardiac rhythm management system or other implantable medical device and a programmer or other remote device. One example provides an inductive near-field communication link between the telemetry interface and the implantable medical device, and a radio-frequency (RF) far-field communication link between the telemetry interface device and the remote device. The telemetry interface device provides data buffering. In another example, the telemetry interface device includes a data processing module for compressing and / or decompressing data, or for extracting information from data. Such information extraction may include obtaining heart rate, interval, and / or depolarization morphology information from an electrogram signal received from the implantable medical device.

An implantable cardiac rhythm management device operable in an autothreshold or autocapture verification mode, wherein the rhythm management device is capable of detecting noise that affects signal characteristics of a sensed intracardial evoked response electrogram signal. The device includes a noise detection circuit that determines whether a minimum peak timing occurs during a predetermined time following delivery of a stimulation pulse. If a minimum peak timing occurs during the predetermined time following delivery of the stimulation pulse, then significant amounts of noise affecting the signal characteristics of the electrocardiogram signal is assumed.

A system delivers cardiac pacing therapy and chemical and / or biological therapy to modulate myocardial tissue growth in a heart after myocardial infarction (MI). The system includes an agent delivery device to release one or more agents to an MI region to modulate myocardial tissue growth in that region, and a cardiac rhythm management (CRM) device to deliver pacing pulses to enhance the effects of the one or more agents by altering myocardial wall stress and cardiac workload. In one embodiment, the system is an implantable system including an implantable agent delivery device and an implantable CRM device.

Systems and methods provide for gathering of patient related data during non-sleep periods and modulating a therapy delivered to the patient during sleep using the gathered data. Data associated with a patient is gathered while the patient is awake. A therapy delivered to the patient during patient sleep is adjusted using the acquired data. The therapy delivered to the patient may include one or more of a respiratory therapy, such as a positive airway pressure (xPAP) therapy, a sleep disordered breathing therapy, a cardiac rhythm management therapy, such as a cardiac overdrive pacing therapy, a medication therapy, or a drug delivery therapy. The therapy delivered to the patient may be optimized using the acquired data.

System and method for monitoring and controlling, defibrillation and pacing which allows a victim of a cardiac rhythm abnormality immediate access to a medical professional at a central station, who will remotely monitor, diagnose and treat the victim at one of a plurality of remote sites in accordance with the following steps: (1) providing a plurality of contact electrodes for a victim at a remote site for the receipt of ECG signals and for the application of electrical pulses to the victim; (2) transmitting the signals from the remote site to a central station and displaying them for review by the medical professional; (3) the medical professional selecting from a menu of defibrillation and pacing pulses, if the application thereof is appropriate; (4) transmitting the selection results to the remote site; and (5) receiving the selection results at the remote site and applying the selected pulses to the victim.

An electrocardiographic device for recording the rhythm of the human heart using a home personal computer and printer. This device consists of three silver-plated leads, a 1000× amplifier, an analog to digital computer, an oscillating timing clock, a microcontroller unit, a USB input bus, a data output bus, and computer software for displaying the rhythm graphically. The advantages of this device include convenience, low cost, and repeatability. A patient can record their cardiac rhythm themselves at any time whenever a sudden cardiac arrhythmia occurs without traveling to the doctor's office or emergency room. Based on the low cost of this inexpensive device a patient can own his own rhythm recording device instead of paying for expensive Holter monitors or event recorders from a doctor's office. Lastly, this device can be used repeatedly without the expense of disposable electrodes or limitations of monitoring device memory restricting the number of electrocardiographic recordings.

A lead system, coupled to an implantable device, is configured for subcutaneous, non-intrathoracic placement relative to a patient's heart. Cardiac activity detection circuitry is coupled to the lead system and configured to detect cardiac rhythms. Disordered breathing detection circuitry is coupled to the lead system and configured to detect disordered breathing. One or both of cardiac therapy circuitry and disordered breathing therapy circuitry may be coupled to the lead system and configured to delivery therapies to treat disordered breathing. Such therapies include cardiac pacing, diaphragmatic pacing, and hypoglossal nerve stimulation therapies. A patient-external respiratory device, such as a positive airway pressure device, may be configured to deliver a disordered breathing therapy. One or more of a patient-internal drug delivery device, a patient-external drug delivery device, or a gas therapy device may be employed to treat disordered breathing.

A system and method for classifying cardiac complexes sensed during a tachycardia episode. A first cardiac signal and a second cardiac signal are sensed, where the first cardiac signal has a voltage. A first cardiac complex and a second cardiac complex of a cardiac cycle are detected in the first and second cardiac signal, respectively. A predetermined alignment feature is identified in the second cardiac complex. A datum is defined, or positioned, at a specified interval from the predetermined alignment feature of the second cardiac complex. Voltage values are then measured from the first cardiac complex at each of two or more measurement intervals from the datum. The voltage values are then compared voltage values measured from NSR cardiac complexes to classify the first cardiac complex is either a ventricular tachycardia complex or a supraventricular tachycardiac complex.

A method and apparatus for determining whether a patient with congestive heart failure (CHF) will benefit from pacing therapy through the use of an implantable cardiac rhythm management device. A patient's right ventricular and left ventricular pressures are measured, and the patient's PP_Area is calculated for each normal heartbeat that occurs during the testing period. Depending upon the value of the patient's mean PP_Area, it can be determined whether the patient will or will not respond well acutely to pacing therapy. A mean PP_Area value of greater than or equal to a predetermined threshold, which is about 0.3, indicates that the patient is a responder to pacing therapy, while a value of less than the predetermined threshold of about 0.3 indicates that the patient is a non-responder.

A lead for use in conjunction with a cardiac rhythm management device includes an electrode coupled to a conductor. The lead includes an insulative covering in the areas distal and proximal to the electrode. The electrode includes one or more slots bridged by the insulative material to form a more secure joint between the electrode and the insulative material.

Systems and methods are described for classifying a cardiac rhythm. A cardiac rhythm is classified using a classification process that includes a plurality of cardiac rhythm discriminators. Each rhythm discriminator provides an independent classification of the cardiac rhythm. The classification process is modified if the modification is likely to produce enhanced classification results. The rhythm is reclassified using the modified classification process.

A cardiac rhythm management system detects hypotension based on a measurement of thoracic impedance. It also provides therapy to treat the hypotension.

An implantable medical device and associated method for automatically generating morphology templates during fast cardiac rhythms, confirming a provisional template as a confirmed template, and using the confirmed template to classify subsequent detected arrhythmias. A provisional SVT template may be created during a fast ventricular rate and activated as a confirmed SVT template upon verification that the fast rate was due to an SVT. The confirmed SVT template may be used to discriminate SVT from VT / VF.

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

A device and method in which spectral analysis of heart rate variability is performed in order to assess autonomic balance. When a threshold level is reached, a diagnostic mode is triggered in which the device performs computationally intensive data analysis to assess the probability of a pathological event such as an arrhythmia occurring.

A method for operating a cardiac rhythm management device in which a clinical state vector is computed as a combination of a plurality of parameters related to a patient's heart failure status and compared to a previously computed clinical state vector to determine a clinical trajectory indicative of changes in the patient's heart failure status. Such detected changes in status can be used both as a clinical tool to evaluate treatment and to automatically adjust the operation of the device.